WithMe Health, a personalized medication guidance company, has raised $20 million in a Series B funding round that closed last week. OMERS Ventures led the round, along with participation from existing investor Oak HC/FT and new investors Section 32, Shulman Ventures and MTS Ventures.
The company also brought on Michael Yang, a managing partner at OMERS Ventures, to join the WithMe Health board of directors and Brian Marcotte, the past CEO and president of the Business Group on Health, to join the company’s advisory board.
The new funding will support further growth of its client base, as well as an extension of its medication guidance core offering.
“We are excited to partner with Joe Murad and the WithMe Health team as they bring a new medication management model to a very traditional pharmacy benefit management market,” Yang said in a statement. “The early traction they’ve had getting new customers onboard is impressive and a clear indication that the need for a product like this is significant and timely.”
Mexico City-based health tech startup Sofía recently announced its Series A funding round worth $19 million, led by Index Ventures.
Sofía began with a telemedicine service that offered free medical video consultations and has since grown to include a technology-enabled health plan. Its health plan offers benefits such as an in-app insurance subscription process, free telemedicine visits, zero deductibles and a rolling reinstatable maximum insured sum.
The funds will help the company further develop its product. Sofía has now raised more than $25 million after it closed a $6.3 million seed round in March.
“Sofía is more than only a telemedicine app, as many others that have been born during the pandemic,” said Sebastián Jiménez-Bonnet, the founder and CPO of Sofía, in a statement. “We’ll make navigating through the healthcare ecosystem simpler and better. With a streamlined experience, our customers will have complete insurance coverage, from treating simple ailments via a video consultation to major events and/or accidents. Services are covered no matter how small, deductible free, and with direct service and support 24/7.”
German digital therapeutics startup Perfood has raised €5 million ($5.9 million) in a Series A funding round to launch its first prescription therapeutics.
Boehringer Ingelheim Venture Fund led the round and was joined by UV-Cap and investiere.
Perfood plans to launch its digital therapeutic for migraine treatment, sinCephalea, with the money. Additionally, it will conduct clinical trials to advance its pipeline of digital therapeutics products powered by personal nutrition.
“With Boehringer Ingelheim Venture Fund, UV-Cap and investiere, Perfood has an outstanding setup to bring sinCephalea onto the market not only in Germany but also internationally,” said Dominik Burziwoda, the founder and CEO of Perfood.
Quantum Health recently announced that private equity firm Warburg Pincus has invested in its consumer healthcare navigation and care coordination platform. Financial terms of the transaction were not disclosed.
“We look forward to partnering with Warburg Pincus, whose successful track record and experience in the healthcare and technology sectors will benefit our company as we continue to grow our business and deliver best-in-class services to our customers,” said Kara Trott, the founder and CEO of Quantum Health, in a statement.
The investment will aid Quantum Health in improving its technology platform and service delivery capabilities for its customer base of self-insured employers.
This content was originally published here.